JP2022507065A5 - - Google Patents
Info
- Publication number
- JP2022507065A5 JP2022507065A5 JP2021525223A JP2021525223A JP2022507065A5 JP 2022507065 A5 JP2022507065 A5 JP 2022507065A5 JP 2021525223 A JP2021525223 A JP 2021525223A JP 2021525223 A JP2021525223 A JP 2021525223A JP 2022507065 A5 JP2022507065 A5 JP 2022507065A5
- Authority
- JP
- Japan
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024091521A JP2024113083A (ja) | 2018-11-13 | 2024-06-05 | Ｎｌｒｐ活性に関連する病態を治療するための化合物及び組成物 |
Applications Claiming Priority (27)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862760248P | 2018-11-13 | 2018-11-13 | |
| US201862760244P | 2018-11-13 | 2018-11-13 | |
| US201862760209P | 2018-11-13 | 2018-11-13 | |
| US62/760,209 | 2018-11-13 | ||
| US62/760,244 | 2018-11-13 | ||
| US62/760,248 | 2018-11-13 | ||
| US201862768811P | 2018-11-16 | 2018-11-16 | |
| US62/768,811 | 2018-11-16 | ||
| US201862769151P | 2018-11-19 | 2018-11-19 | |
| US201862769165P | 2018-11-19 | 2018-11-19 | |
| US62/769,165 | 2018-11-19 | ||
| US62/769,151 | 2018-11-19 | ||
| US201962795919P | 2019-01-23 | 2019-01-23 | |
| US62/795,919 | 2019-01-23 | ||
| US201962796356P | 2019-01-24 | 2019-01-24 | |
| US201962796361P | 2019-01-24 | 2019-01-24 | |
| US62/796,361 | 2019-01-24 | ||
| US62/796,356 | 2019-01-24 | ||
| US201962836577P | 2019-04-19 | 2019-04-19 | |
| US201962836585P | 2019-04-19 | 2019-04-19 | |
| US201962836575P | 2019-04-19 | 2019-04-19 | |
| US62/836,585 | 2019-04-19 | ||
| US62/836,577 | 2019-04-19 | ||
| US62/836,575 | 2019-04-19 | ||
| US201962895595P | 2019-09-04 | 2019-09-04 | |
| US62/895,595 | 2019-09-04 | ||
| PCT/US2019/060770 WO2020102096A1 (en) | 2018-11-13 | 2019-11-11 | Compounds and compositions for treating conditions associated with nlrp activity |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024091521A Division JP2024113083A (ja) | 2018-11-13 | 2024-06-05 | Ｎｌｒｐ活性に関連する病態を治療するための化合物及び組成物 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022507065A JP2022507065A (ja) | 2022-01-18 |
| JPWO2020102096A5 JPWO2020102096A5 (https=) | 2022-11-22 |
| JP2022507065A5 true JP2022507065A5 (https=) | 2022-11-22 |
| JP7730759B2 JP7730759B2 (ja) | 2025-08-28 |
Family
ID=68841175
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021525223A Active JP7730759B2 (ja) | 2018-11-13 | 2019-11-11 | Ｎｌｒｐ活性に関連する病態を治療するための化合物及び組成物 |
| JP2024091521A Pending JP2024113083A (ja) | 2018-11-13 | 2024-06-05 | Ｎｌｒｐ活性に関連する病態を治療するための化合物及び組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024091521A Pending JP2024113083A (ja) | 2018-11-13 | 2024-06-05 | Ｎｌｒｐ活性に関連する病態を治療するための化合物及び組成物 |
Country Status (31)
| Country | Link |
|---|---|
| US (1) | US20230031406A1 (https=) |
| EP (2) | EP3880660B1 (https=) |
| JP (2) | JP7730759B2 (https=) |
| KR (1) | KR20210096123A (https=) |
| CN (2) | CN113166065B (https=) |
| AU (1) | AU2019379109B2 (https=) |
| BR (1) | BR112021008969A2 (https=) |
| CA (1) | CA3114918A1 (https=) |
| CL (1) | CL2021001228A1 (https=) |
| CO (1) | CO2021006075A2 (https=) |
| CR (1) | CR20210235A (https=) |
| DK (1) | DK3880660T3 (https=) |
| EC (2) | ECSP21033236A (https=) |
| ES (1) | ES3042546T3 (https=) |
| FI (1) | FI3880660T3 (https=) |
| HR (1) | HRP20251344T1 (https=) |
| HU (1) | HUE073575T2 (https=) |
| IL (1) | IL283042B2 (https=) |
| JO (1) | JOP20210105B1 (https=) |
| LT (1) | LT3880660T (https=) |
| MA (1) | MA54229B1 (https=) |
| MX (1) | MX2021005529A (https=) |
| MY (1) | MY206733A (https=) |
| PE (1) | PE20211698A1 (https=) |
| PH (1) | PH12021500025A1 (https=) |
| PL (1) | PL3880660T3 (https=) |
| PT (1) | PT3880660T (https=) |
| RS (1) | RS67257B1 (https=) |
| SG (1) | SG11202103405TA (https=) |
| SI (1) | SI3880660T1 (https=) |
| WO (1) | WO2020102096A1 (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3649112A1 (en) * | 2017-07-07 | 2020-05-13 | Inflazome Limited | Sulfonylureas and sulfonylthioureas as nlrp3 inhibitors |
| EP3668843A1 (en) | 2017-08-15 | 2020-06-24 | Inflazome Limited | Sulfonylureas and sulfonylthioureas as nlrp3 inhibitors |
| MA49903A (fr) | 2017-08-15 | 2020-06-24 | Inflazome Ltd | Sulfonylureés et sulfonylthioureés en tant qu'inhibiteurs de nlrp3 |
| UY37848A (es) | 2017-08-15 | 2019-03-29 | Inflazome Ltd | Sulfonilureas y sulfoniltioureas útiles como inhibidores de nlrp3 |
| WO2019092171A1 (en) | 2017-11-09 | 2019-05-16 | Inflazome Limited | Novel sulfonamide carboxamide compounds |
| CN111315733A (zh) | 2017-11-09 | 2020-06-19 | 英夫拉索姆有限公司 | 新颖磺酰胺甲酰胺化合物 |
| US11905252B2 (en) | 2018-03-02 | 2024-02-20 | Inflazome Limited | Compounds |
| CA3105521A1 (en) | 2018-07-20 | 2020-01-23 | F. Hoffmann-La Roche Ag | Sulfonimidamide compounds as inhibitors of interleukin-1 activity |
| JP7392169B2 (ja) * | 2019-11-12 | 2023-12-05 | 成都百裕制薬股▲ふん▼有限公司 | アミド誘導体及びその調製方法並びに医薬における応用 |
| PH12022551767A1 (en) * | 2020-01-22 | 2023-11-29 | Hoffmann La Roche | Sulfonimidamide compounds as nlrp3 modulators |
| WO2022023907A1 (en) | 2020-07-31 | 2022-02-03 | Novartis Ag | Methods of selecting and treating patients at elevated risk of major adverse cardiac events |
| CN117279903A (zh) * | 2021-02-10 | 2023-12-22 | 杭州英创医药科技有限公司 | 作为nlrp3抑制剂的化合物 |
| US11932630B2 (en) | 2021-04-16 | 2024-03-19 | Novartis Ag | Heteroaryl aminopropanol derivatives |
| CN116635373A (zh) * | 2021-05-10 | 2023-08-22 | 成都百裕制药股份有限公司 | 酰胺衍生物及其应用 |
| CN116917282A (zh) * | 2021-05-10 | 2023-10-20 | 成都百裕制药股份有限公司 | 酰胺衍生物及其应用 |
| CN116635374B (zh) * | 2021-05-10 | 2025-05-06 | 康百达（四川）生物医药科技有限公司 | 酰胺衍生物及其应用 |
| CN114989058B (zh) * | 2022-06-02 | 2024-04-16 | 中国科学院成都生物研究所 | 一种手性氯代砜亚胺类化合物及其衍生物的制备方法 |
| CN115974745B (zh) * | 2022-12-27 | 2025-06-03 | 瑞石生物医药有限公司 | 一类含引达省的化合物及其医药用途 |
| CN116253664A (zh) * | 2023-02-01 | 2023-06-13 | 山东海科创新研究院有限公司 | 基于双液相微乳化缩合工艺的accp制备方法 |
| WO2025153532A1 (en) | 2024-01-16 | 2025-07-24 | NodThera Limited | Nlrp3 inhibitors and glp-1 agonists combination therapies |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI3259253T1 (sl) * | 2015-02-16 | 2020-07-31 | The University Of Queensland | Sulfonilsečnine in sorodne spojine ter njihova uporaba |
| US11339136B2 (en) * | 2016-04-18 | 2022-05-24 | Novartis Ag | Compounds and compositions for treating conditions associated with NLRP activity |
| JP7349981B2 (ja) * | 2017-07-24 | 2023-09-25 | ノバルティス アーゲー | Ｎｌｒｐ活性に関連する状態を治療するための化合物及び組成物 |
| ES2988798T3 (es) * | 2017-07-24 | 2024-11-21 | Novartis Ag | Compuestos y composiciones para el tratamiento de afecciones asociadas a la actividad de NLRP |
| CA3105521A1 (en) * | 2018-07-20 | 2020-01-23 | F. Hoffmann-La Roche Ag | Sulfonimidamide compounds as inhibitors of interleukin-1 activity |
-
2019
- 2019-11-11 ES ES19817831T patent/ES3042546T3/es active Active
- 2019-11-11 MY MYPI2021002584A patent/MY206733A/en unknown
- 2019-11-11 CR CR20210235A patent/CR20210235A/es unknown
- 2019-11-11 DK DK19817831.1T patent/DK3880660T3/da active
- 2019-11-11 MX MX2021005529A patent/MX2021005529A/es unknown
- 2019-11-11 EP EP19817831.1A patent/EP3880660B1/en active Active
- 2019-11-11 JP JP2021525223A patent/JP7730759B2/ja active Active
- 2019-11-11 PL PL19817831.1T patent/PL3880660T3/pl unknown
- 2019-11-11 RS RS20250973A patent/RS67257B1/sr unknown
- 2019-11-11 IL IL283042A patent/IL283042B2/en unknown
- 2019-11-11 WO PCT/US2019/060770 patent/WO2020102096A1/en not_active Ceased
- 2019-11-11 HU HUE19817831A patent/HUE073575T2/hu unknown
- 2019-11-11 PH PH1/2021/500025A patent/PH12021500025A1/en unknown
- 2019-11-11 LT LTEPPCT/US2019/060770T patent/LT3880660T/lt unknown
- 2019-11-11 EP EP25186277.7A patent/EP4667054A3/en active Pending
- 2019-11-11 HR HRP20251344TT patent/HRP20251344T1/hr unknown
- 2019-11-11 KR KR1020217017180A patent/KR20210096123A/ko active Pending
- 2019-11-11 CN CN201980074397.XA patent/CN113166065B/zh active Active
- 2019-11-11 PE PE2021000700A patent/PE20211698A1/es unknown
- 2019-11-11 MA MA54229A patent/MA54229B1/fr unknown
- 2019-11-11 FI FIEP19817831.1T patent/FI3880660T3/fi active
- 2019-11-11 US US17/292,881 patent/US20230031406A1/en active Pending
- 2019-11-11 SG SG11202103405TA patent/SG11202103405TA/en unknown
- 2019-11-11 BR BR112021008969-1A patent/BR112021008969A2/pt unknown
- 2019-11-11 SI SI201930974T patent/SI3880660T1/sl unknown
- 2019-11-11 CN CN202510396657.2A patent/CN120531732A/zh active Pending
- 2019-11-11 AU AU2019379109A patent/AU2019379109B2/en active Active
- 2019-11-11 CA CA3114918A patent/CA3114918A1/en active Pending
- 2019-11-11 PT PT198178311T patent/PT3880660T/pt unknown
-
2021
- 2021-05-10 JO JOJO/P/2021/0105A patent/JOP20210105B1/ar active
- 2021-05-10 CO CONC2021/0006075A patent/CO2021006075A2/es unknown
- 2021-05-11 CL CL2021001228A patent/CL2021001228A1/es unknown
- 2021-05-11 EC ECSENADI202133236A patent/ECSP21033236A/es unknown
-
2024
- 2024-06-05 JP JP2024091521A patent/JP2024113083A/ja active Pending
- 2024-06-07 EC ECSENADI202444340A patent/ECSP24044340A/es unknown